Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06954493 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
A Phase 1 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06954493 is a Phase 1 study that has completed, run by Scynexis. The registered enrollment target is 5 participants.
The verdict
NCT06954493, a Phase 1 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening
Interventions
- DRUG Ibrexafungerp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06954493
The ClinicalTrials.gov registry entry for NCT06954493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrexafungerp is the first listed.
NCT06954493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06954493 about?
NCT06954493 is a clinical study titled "Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp". This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening
What is the current status of trial NCT06954493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2023-07-12. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT06954493?
The interventions under investigation include: Ibrexafungerp (DRUG).
Who is sponsoring clinical trial NCT06954493?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.